Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00737217
• Other study ID #: 2005-0464
• Status: Completed
• Phase: N/A
• First received: August 15, 2008
• Last updated: June 24, 2013
• Start date: March 2006
• Est. completion date: April 2009

Study information

• Verified date: June 2013
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This research study will evaluate functions of memory, thinking, behavior, and daily life activities and how these relate to the measurement of certain chemicals (acetylcholine and dopamine) in the brain using an imaging procedure called positron emission tomography (PET). You may know that in Alzheimer's dementia (dementia is a disease where persons become forgetful and confused), a reduction in the amount of acetylcholine, a "neurotransmitter" substance (a chemical messenger that nerve cells need to communicate with each other), may be responsible for some of the memory and behavioral changes. At the present time, the investigators have no clear information on the levels of acetylcholine in the brain of patients with Parkinson's disease who also have memory or behavioral changes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: April 2009
• Est. primary completion date: April 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

• PDD: Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria for PD with dementia (MMSE 18-25; n=28; age 50-85 years; M/F) are eligible for the study. Hoehn and Yahr stages I-III.

• PD. Patients with who meet the UKPDSBRC criteria for PD with a MMSE of >25 (n=28; age 50-85 years; M/F). Hoehn and Yahr stages I-III.

• Normal control subjects (n=16) (age 50-85 years; M/F).

• No current or past history of neurologic or psychiatric illness.

Exclusion Criteria:

• Any subjects on cholinergic, anti-cholinergic drugs will be excluded from the study.

• Current or past history of neurologic or psychiatric illness.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Behavioral:
• Behavioral assessment/questionnaire
Complete behavioral assessment/questionnaire

Locations

Country	Name	City	State
United States	University of Michigan Functional, Cognitive and Mobility Laboratory	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan	Michael J. Fox Foundation for Parkinson's Research

Country where clinical trial is conducted

United States,